ArticleFrontiers in veterinary science2025
Protective efficacy of inactivated FHV-1 vaccine in cats following challenge with the Chinese field strains.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Non-linear pharmacokinetics of penciclovir in healthy cats after single and multiple oral administration of famciclovir.Frontiers in veterinary science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Feline herpesvirus-1 (FHV-1) is a leading cause of feline viral rhinotracheitis (FVR), which mainly presents upper respiratory tract symptoms. Vaccination is the most effective strategy for controlling FHV-1. Prior to the initiation of this study, China does not have domestically produced commercially available FHV-1 vaccines using field strain as antigenic component and most corresponding imported vaccines contained feline viral rhinotracheitis, calicivirus, and panleukopenia (FVRCP) antigens. However, the protective efficacy of these vaccines against the prevalent FHV-1 strains in China remains unclear. In the present study, a total of 12 cats were randomly divided into 3 groups, which were vaccinated with FHV-1 field vaccine (Group 1 [an inactivated vaccine developed by ourselves using the Chinese field strain FHV-1 2020GD02]) and FVRCP vaccine (Group 2) and PBS (Group 3) as control, respectively. These animals received two vaccinations with a 21-day interval and were challenged with 2020GD02 at 21 days after the second vaccination. Clinical signs, serological responses, viral shedding, and histopathological changes were used to estimate protective efficacy of the two vaccines. Compared to Group 2, animals in Group 1 produced higher level FHV-1 antibody titers during immune processes. After challenge, Group 3 developed typical FVR. In contrast, animals in both Groups 1 and 2 showed significantly fewer clinical signs, viral shedding, and pathological changes, but could not provide complete protection. Our results provided a reference for further FHV-1 vaccines development in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.